E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

  • Law Blogs

Become a Fan

« USPTO Expands Application Exchange Program | Main | GSK Promotes Open Innovation by Sharing Malaria Inhibitor Compounds »

May 25, 2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d83451ca1469e20133ee9aab21970b

Listed below are links to weblogs that reference Marks & Clerk Survey Predicts Rise in Consolidation as Biotech/Pharma Industry Nears Patent Cliff:

Comments

I think it is self-evident that the industry will go through a shake out/consolidation period. I would expect more pharma/biotech mergers. I think companies will develop product portfolios that include branded small & large molecules, generics and biosimilars. There will be more partnering too. And, there will be greater geogrpahic dispersion amongst the 'world class' companies - they won't all end up being in US and EU. The AP and other pharmerging regions will grow as predicted and will spawn some heavyweights of their own.

bigredbruce http://bit.ly/aD2oJV

Back in the biotech pleistocene I was under the naive impression that the molecular biologists would unleash a flood of new pharma targets and unwind the etiology of many diseases, all of great benefit to pharma. I had less hopes for iterative drug design, but what the heck - it was bound to help! Oh well. I'm now reduced to placing my bets on Indian/Chinese knock-off artists deciding to go innovator because they can do drug research at small fractions of the cost in major industrialized countries. But they would need a change in attitude, not likely. So I guess I should be grateful I'm retired. The Golden Age of pharmaceuticals is behind us, and Obamacare will deliver the coup de grace despite the authors' conclusions.

The comments to this entry are closed.

April 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30